Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Camrelizumab + Apatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07618546Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2026
- Primary completion
- Mar 2027
01
Overview
Randomised, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Event-Free Survival at 42 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07618546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618546.